Vaginal ALK-positive anaplastic large cell lymphoma treated with brentuximab vedotin: a case report and literature review

Cortez, Anita Cassoli; Costa, Felipe D’Almeida; Silveira, Talita

doi:10.1016/j.htct.2022.01.008

Cited by 2 publications

(6 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…To our knowledge, this is the first report of ALK+ ALCL with dissemination to the gynecologic tract. Only two reports of the same histologic subtype involving the gynecologic tract appear in the literature, both of which describe primary extranodal ALK+ ALCL of the vagina [ 5 , 6 ]. The first report describes stage II disease with involvement of the bladder that initially presented as a vaginal mass in a 52-year-old with chronic renal failure.…”

Section: Discussionmentioning

confidence: 99%

“…Immunohistochemically, this case shared positive CD30 and ALK markers with our case; however, positive CD3 and negative CD43 were also present, which were the opposite findings in our case. Unfortunately, the patient deteriorated quickly and died two weeks after the initial biopsy before treatment could be initiated [ 5 , 6 ]. The second report describes stage I disease that initially presented as a vaginal lesion with associated fevers in a healthy 35-year-old.…”

Section: Discussionmentioning

confidence: 99%

“…Immunohistochemistry was positive for CD4, CD43, CD30, and ALK, identical to our case. The patient had a complete response to treatment with systemic chemotherapy (BV-CHP) as of one-year follow-up [ 6 ]. The patient’s outcome beyond this time is unknown.…”

Section: Discussionmentioning

confidence: 99%

“…Herein, we describe a case of anaplastic lymphoma kinase (ALK)-positive anaplastic large cell lymphoma (ALK+ ALCL) with secondary involvement of the uterus and cervix successfully treated with systemic chemotherapy. Only two cases of the same histologic subtype involving the gynecologic tract have been reported to date, both of which describe primary disease of the vagina [ 5 , 6 ].…”

Section: Introductionmentioning

confidence: 99%

“…The majority of cases are of B-cell origin, with diffuse large B-cell lymphoma (DLBCL) being the most common histologic subtype [1,3]. T-cell lymphomas involving the gynecologic tract are far less common and typically have a poor prognosis [1][2][3][4][5][6][7]. Herein, we describe a case of anaplastic lymphoma kinase (ALK)-positive anaplastic large cell lymphoma (ALK+ ALCL) with secondary involvement of the uterus and cervix successfully treated with systemic chemotherapy.…”

Section: Introductionmentioning

confidence: 99%

See 4 more Smart Citations

Disseminated Anaplastic Lymphoma Kinase (ALK)-Positive T-cell Lymphoma Involving the Uterus and Cervix: A Case Report

Yang,

Sabri,

Awad

et al. 2024

Cureus

View full text Add to dashboard Cite

Primary or secondary non-Hodgkin lymphomas (NHLs) involving the female gynecologic tract are rare. T-cell subtypes are further rare and portend a worse prognosis. We present a case of a 23-year-old female presenting with a cervical mass accompanied by constitutional symptoms and abnormal vaginal bleeding. Immunohistochemistry studies revealed the presence of disseminated T-cell non-Hodgkin lymphoma that was anaplastic lymphoma kinase (ALK)-positive. The patient demonstrated a complete response to systemic chemotherapy initially and again after the relapse of the disease one year after diagnosis. To our knowledge, this is the first case of an ALK-positive T-cell lymphoma with secondary involvement of the uterus and cervix; all previously published cases of this histologic subtype in the gynecologic tract describe primary disease of the vagina. This case emphasizes the importance of immunohistochemistry studies inclusive of T-cell and B-cell markers when evaluating biopsies from cervical tumors to render the appropriate diagnosis and guide systemic therapy.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%